Publications by authors named "Janna Yu"

Claim this Profile
T
The JAK1/2 inhibitor ruxolitinib downregulates the immune checkpoint protein B7H3 in multiple myeloma.
Ning Xu, Erin Yu, Nicole Ng, Mingjie Li, Sean Bujarski, Janna Yu

Hematol Oncol· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Ruxolitinib reverses checkpoint inhibition by reducing programmed cell death ligand-1 (PD-L1) expression and increases anti-tumour effects of T cells in multiple myeloma.
Haiming Chen, Mingjie Li, Nicole Ng, Erin Yu, Sean Bujarski, Janna Yu

Br J Haematol· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis